Immuron (STU:ANWA) ROE % Adjusted to Book Value : -24.68% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Immuron ROE % Adjusted to Book Value?

Immuron's ROE % for the quarter that ended in Dec. 2023 was -22.21%. Immuron's PB Ratio for the quarter that ended in Dec. 2023 was 0.90. Immuron's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -24.68%.

Immuron ROE % Adjusted to Book Value Historical Data

The historical data trend for Immuron's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron ROE % Adjusted to Book Value Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-6.23

-41.47

-17.79

-22.39

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial												-17.40	-13.48	-20.24	-22.93	-24.68

Competitive Comparison of Immuron's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Immuron's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Immuron's ROE % Adjusted to Book Value falls into.

Immuron ROE % Adjusted to Book Value Calculation

Immuron's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-17.02%	/	0.76
	=	-22.39%

Immuron's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-22.21%	/	0.90
	=	-24.68%

Immuron ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Immuron's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (STU:ANWA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines